Purpose In peptide receptor radionuclide therapy (PRRT), the bone marrow (BM) is one of
the dose-limiting organs. The accepted dose limit for BM is 2 Gy, adopted from 131 I treatment…

Purpose After peptide receptor radionuclide therapy (PRRT), renal toxicity may occur, particular
in PRRT with 90 Y-labelled somatostatin analogues. Risk factors have been identified …

Purpose Gastrin-releasing peptide receptors (GRPR) represent attractive targets for tumor
diagnosis and therapy because of their overexpression in major human cancers. Internalizing …

Peptide receptor radionuclide therapy (PRRT) may induce long-term toxicity to the bone
marrow (BM). The aim of this study was to analyze persistent hematologic dysfunction (PHD) …

Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues
plays an increasing role in the treatment of patients with inoperable or metastasised …

Response Evaluation Criteria In Solid Tumors (RECIST) (unidimensional), Southwest Oncology
Group (SWOG) solid tumor response criteria (bidimensional), and their modified variants …

Peptide Receptor Radionuclide Therapy (PRRT) may induce long-term toxicity to the bone
marrow (BM). The aim of this study was to analyze persistent dysfunction of the hematopoietic …

583 Objectives We have recently reported on [ 68 Ga]SB3 ([ 68 Ga-DOTA-p-aminomethylaniline-diglycolic
acid-DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-NHEt), a high affinity GRPR (gastrin …

280 Objectives Gastrin-releasing Peptide Receptors (GRP-R) are expressed at high levels in
prostate- and breast cancer, thereby providing attractive targets for GRP-R specific imaging …

… Hendrik Bergsma … Bergsma, Rotterdam, The Netherlands. All rights reserved. No part
of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or …